Core Viewpoint - The company reported a mixed performance in Q3 2025, with revenue growth but a decline in net profit, primarily due to product price changes and fluctuations in investment income [1] Financial Performance - For the first three quarters of 2025, the company achieved revenue of 1.015 billion, a year-on-year increase of 4.66%, while net profit attributable to shareholders was 429 million, a decrease of 22.46% [1] - In Q3 2025, the company recorded revenue of 300 million, a significant year-on-year increase of 64.68%, but net profit decreased by 23.63% to 114 million [1] - The gross profit margin for the first three quarters of 2025 fell by 5.10 percentage points to 70.40%, mainly due to product price reductions [4] International Business Growth - The company has been actively expanding its international business, achieving over 95% growth in overseas sales revenue in the first half of 2025, with international sales accounting for 17% of total revenue [1] - As of mid-2025, the company obtained 8 new product registration certificates overseas, bringing the total to over 100, covering 45 countries and regions [2] R&D Progress - The company has made significant advancements in R&D, with several products in various stages of approval and clinical trials, including the Cratos branched aortic stent and Hector multi-branch aortic stent system [3] - The company is also progressing in the peripheral artery intervention and oncology intervention fields, with multiple products undergoing clinical applications and regulatory reviews [3] Expense and Profitability Analysis - The company experienced an increase in expense ratios, with sales expense ratio rising by 5.40 percentage points to 14.92% due to increased overseas promotion efforts [4] - In Q3 2025, the overall net profit margin saw a significant decline of 44.05%, influenced by changes in investment income [4] Future Outlook - The company forecasts revenue growth for 2025-2027, with expected revenues of 1.489 billion, 1.852 billion, and 2.350 billion, representing year-on-year growth rates of 23.43%, 24.38%, and 26.89% respectively [5] - The projected net profit for the same period is expected to be 603 million, 755 million, and 964 million, with corresponding growth rates of 20.14%, 25.08%, and 27.80% [5]

Summary of Key Points Core Viewpoint - The company, Xinmai Medical, is undergoing significant governance changes, including the cancellation of its supervisory board and the introduction of new management policies, which may impact its operational structure and risk management strategies [1][3]. Trading Information - On November 5, 2025, Xinmai Medical's stock closed at 98.15 yuan, down 1.2%, with a turnover rate of 1.3% and a trading volume of 16,000 hands, resulting in a transaction value of 1.58 billion yuan [1]. - The net outflow of main funds on the same day was 11.473 million yuan, accounting for 7.27% of the total transaction value [1][3]. - Retail investors showed a net inflow of 18.9695 million yuan, representing 12.03% of the total transaction value [1]. Company Announcements - Xinmai Medical will hold its first extraordinary general meeting of shareholders on November 14, 2025, to discuss three key proposals: 1. The cancellation of the supervisory board, with its functions transferred to the audit committee of the board of directors, along with amendments to the company's articles of association and necessary business registration changes. 2. Amendments to eight management regulations, including the rules for shareholder meetings and board meetings, in accordance with the new Company Law and relevant regulatory requirements. 3. The proposal to purchase liability insurance for directors and senior management with an annual coverage of 50 million yuan and a premium not exceeding 300,000 yuan, with a 12-month insurance period [1].

Group 1: Company Highlights - Aihuilong has completed the prototype of its second-generation sequencing project, achieving full self-research and production of core reagents, auxiliary reagents, and auxiliary enzyme reagents, with various patented technologies [1] - Aibo Medical has developed the Puno Tong AI digital fitting system independently [1] - Xinmai Medical reported a revenue of 300 million yuan and a net profit of 114 million yuan for Q3 2025, with a 60% year-on-year increase in net profit after excluding government subsidies [2] - Zhonglian Heavy Industry possesses a national A-level and international T3+ level supercomputing center, with a GPU computing power of 59P, supporting 1,000 cabinets and 10,000 servers [3] Group 2: Financial Performance - Xinmai Medical's domestic sales growth rate remains above 20% for the first three quarters, with overseas revenue increasing by over 65%, accounting for 18% of total revenue [2] - Xinmai Medical expects its annual gross margin to recover to over 70% due to improved production efficiency and cost optimization [2] - Guangfa Fund has an asset management scale of 1,540.246 billion yuan, ranking 3rd among 211 [3] Group 3: Market Activities - Guangfa Fund participated in various company performance briefings and site visits, indicating active engagement in the market [1][2][3] - The latest public fund product launched by Guangfa Fund is the Guangfa CSI 300 Index Quantitative Enhancement A, with a subscription period from November 3 to November 21, 2025 [3]

截至2025年11月4日收盘，心脉医疗（688016）报收于99.34元，较前一交易日下跌2.85%，最新总市值 为122.45亿元。该股当日开盘101.98元，最高102.2元，最低99.03元，成交额达1.66亿元，换手率为 1.34%。 《心脉医疗：2025年第一次临时股东大会会议资料》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 最新公告列表 近日，心脉医疗发布《2025年第一次临时股东大会会议资料》公告，宣布公司将于2025年11月14日召开 2025年第一次临时股东大会。本次会议将审议多项重要议案，其中最受投资者关注的一项为：拟取消公 司监事会，原监事会职权由董事会审计委员会行使，并相应修订《公司章程》及办理工商变更登记。此 外，公司还计划根据新《公司法》及相关监管规定，对《股东会议事规则》《董事会议事规则》《关联 交易管理制度》等八项制度进行修订，并新增部分管理制度。同时，为完善风险管理，公司拟为董事及 高级管理人员购买责任保险，保额为5,000万元/年，保费不超过30万元/年，保险期限为12个月，相关事 项将提请 ...

Core Viewpoint - Xinpai Medical announced the appointment of Ms. Yan Dongmei as the new Secretary of the Board, following her completion of the training program at the Shanghai Stock Exchange for the Sci-Tech Innovation Board [1] Group 1 - Ms. Yan Dongmei has participated in the training and obtained the certification required for the position of Secretary of the Board [1] - Her qualifications have been officially recorded with the Shanghai Stock Exchange [1] - Ms. Yan will serve in this role until the end of the current term of the company's third Board of Directors [1] Group 2 - Mr. Zhu Qing, who previously held the position, will no longer act as the Secretary of the Board [1]

Group 1 - The core point of the article is that Xinpai Medical (688016) announced that Yan Dongmei has completed the training for the position of Secretary of the Board at the Shanghai Stock Exchange and has obtained the relevant certification [1] - Yan Dongmei's qualifications as Secretary of the Board have been filed with the Shanghai Stock Exchange [1] - Yan Dongmei will officially assume the responsibilities of the Secretary of the Board from the date of obtaining the certification until the expiration of the current Board's term [1]

邮政编码：201318 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 为加强上海微创心脉医疗科技（集团）股份有限公司（以下简称"公司"） 内部运营管理效率，确保董事会工作正常运行，经公司董事长提名，董事会提名 委员会资格审查，公司于 2025 年 9 月 30 日召开第三届董事会第九次会议，审议 通过了《关于聘任董事会秘书的议案》，同意聘任严冬梅女士为公司董事会秘书， 具体详见公司于 2025 年 10 月 1 日发布的《关于副总经理兼董事会秘书离任暨聘 任董事会秘书的公告》（公告编号：2025-038）。 严冬梅女士已参加上海证券交易所举办的科创板董事会秘书任职培训，并取 得科创板董事会秘书任职培训证明。严冬梅女士的董事会秘书任职资格已在上海 证券交易所备案。严冬梅女士自取得科创板董事会秘书任职培训证明之日起正式 履行公司董事会秘书职责，任期至公司第三届董事会任期届满之日止。公司董事 兼总经理朱清先生不再代行董事会秘书职责。 严冬梅女士联系方式如下： 联系地址：上海市浦东新区康新公路 3399 弄 1 号楼 2 层 证 ...

证券代码：688016 证券简称：心脉医疗 公告编号：2025-046 上海微创心脉医疗科技（集团）股份有限公司 关于参加 2025 年上海辖区上市公司三季报集体业绩 说明会的公告 会议召开方式：上证路演中心网络文字互动 投资者可于 2025 年 11 月 06 日 （星期四） 至 11 月 12 日 （星期三）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 irm@endovastec.com 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 上海微创心脉医疗科技（集团）股份有限公司（以下简称"公司"）已于 2025 年 10 月 30 日发布公司 2025 年第三季度报告，为便于广大投资者更全面深 入地了解公司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 11 月 13 日（星期四） 15:00-16:30 参加 2025 年上海辖区上市公司三季报集体业绩说 明会，就投资者关心的问题进行交流。 一、 说明会类型 本次业绩说明会以网络文字互动形式召开，公司将针对 2025 年第三季度的 经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信 ...

上海微创心脉医疗科技（集团）股份有限公司 2025 年第一次临时股东大会会议资料 证券代码：688016 证券简称：心脉医疗 上海微创心脉医疗科技（集团）股份有限公司 2025 年第一次临时股东大会 会议资料 | 2025 年第一次临时股东大会会议须知 | 2 | | --- | --- | | 2025 年第一次临时股东大会会议议程 | 4 | | 2025 年第一次临时股东大会会议议案 | 6 | | 议案一：关于取消监事会并修订《公司章程》及办理工商变更登记的议案 | 6 | | 议案二：关于修订及新增公司部分管理制度的议案 | 7 | | 议案三：关于购买董事及高级管理人员责任险的议案 8 | | 上海微创心脉医疗科技（集团）股份有限公司 2025 年第一次临时股东大会会议资料 上海微创心脉医疗科技（集团）股份有限公司 2025 年第一次临时股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证大会的 顺利进行，根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上市公司 股东会规则》以及《上海微创心脉医疗科技（集团）股份有限公司章程》、《上海微创 心脉医疗科技（集 ...

截至9月30日，心脉医疗股东户数1.60万，较上期减少8.73%；人均流通股7708股，较上期增加9.56%。 2025年1月-9月，心脉医疗实现营业收入10.15亿元，同比增长4.66%；归母净利润4.29亿元，同比减少 22.46%。 分红方面，心脉医疗A股上市后累计派现10.79亿元。近三年，累计派现8.17亿元。 11月4日，心脉医疗盘中下跌2.00%，截至10:43，报100.20元/股，成交6044.41万元，换手率0.49%，总 市值123.51亿元。 资金流向方面，主力资金净流出424.60万元，特大单买入431.71万元，占比7.14%，卖出912.96万元，占 比15.10%；大单买入1172.43万元，占比19.40%，卖出1115.77万元，占比18.46%。 心脉医疗今年以来股价跌7.42%，近5个交易日跌3.73%，近20日跌6.31%，近60日跌10.67%。 资料显示，上海微创心脉医疗科技(集团)股份有限公司位于上海市浦东新区康新公路3399弄1号，成立 日期2012年8月17日，上市日期2019年7月22日，公司主营业务涉及主动脉及外周血管介入医疗器械的研 发、生产和销售。主 ...